Sinensis Life Sciences B.V., Leiden, the Netherlands announced that it has acquired Spinnovation Holding B.V., Oss, the Netherlands, a contract research organisation specialised in the application of nuclear magnetic resonance (NMR) techniques in the pharmaceutical and biotechnological market. Financial terms of the transaction were not disclosed.
Galapagos NV announced that more than 100 patients have completed the six month Darwin 1 and 2 studies with GLPG0634 in rheumatoid arthritis and entered Darwin 3, the long term extension study. With the support of their treating physicians, over 90% of the patients who participated in Darwin 1 and Darwin 2 have chosen to participate in Darwin 3, in which all patients will receive long term treatment with Galapagos' highly selective JAK1 inhibitor.
Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophyPublished : Wednesday, September 17, 2014
Prosensa Holding N.V., the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that a comprehensive program of re-dosing has commenced, with the first patients now re-dosed in the United States. All dosing in the drisapersen clinical program had been placed on hold by GSK on September 20, 2013, upon announcement of the DEMAND III study results.
MIMETAS, in a consortium with Radboudumc (Nijmegen) and FHNW (Basel), has received 1.6 million USD funding for development of a kidney-on-a-chip for toxicological applications. A panel of experts from GlaxoSmithKline, Pfizer, Roche, NC3Rs and renowned academic institutions selected MIMETAS’ solution from a strong line-up of competing technologies.
Entrepreneurs can now apply for additional support of the “Oranje Handelsmissiefonds” (abbreviated OHMF) in realizing their international ambitions. From the applicants, ten promising SMEs will be selected and supported with a trade mission package. They will receive a symbolic cheque of €10,000 for – among other – participation in a fully guided trade mission or international fair.
> Read more in Dutch
Between October 27 and November 4 an economic mission will be organized to Japan and South Korea, headed by Minister Henk Kamp. The mission coincides with the state visit of King Willem-Alexander and Queen Máxima to Japan. The trade mission provides an opportunity to companies and research institutions to explore the market, make new contacts or tighten existing contacts.
> Read more in Dutch
Pharming sounded the gong to open Amsterdam market to mark a summer of significant strategic progress for PharmingPublished : Tuesday, September 2, 2014
Pharming and Salix announce initiation of clinical study of RUCONEST® for prophylaxis of hereditary angioedemaPublished : Thursday, August 28, 2014
Pharming acquires new product leads through the acquisition of certain assets of TRM SASU for € 0.5 Million in cashPublished : Tuesday, August 19, 2014
Biotech company Pharming Group NV announced that through the acquisition of certain assets of Transgenic Rabbit Models SASU (TRM), a private French company in liquidation; for € 0.5 million in cash, it has gained access to five potential new product leads (founder rabbits); recombinant- human (rh)-α-glucosidase for the treatment of Pompe’s disease, rh-α-galactosidase for the treatment of Fabry’s disease, rh-β-cerebrosidase for the treatment of Gaucher’s disease, rh- Factor VIII for the treatment of Haemophilia-A and rh- Factor IX for the treatment of Haemophilia-B.
Dutch drug developer ProQR Therapeutics is swinging for a $75 million Wall Street debut to fund its work on a treatment for cystic fibrosis, looking to compete with market leader Vertex Pharmaceuticals ($VRTX). The company, co-founded by former Genzyme CEO Henri Termeer, is preparing a first clinical trial for its lead candidate, QR-010, an RNA-based therapy for CF.
Prosensa and CureDuchenne strengthen long-term collaboration with an additional € 5 million to advance DMD pipelinePublished : Monday, August 11, 2014
Prosensa Holding N.V., the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that an affiliate of CureDuchenne, a US national nonprofit organization dedicated to finding a cure for Duchenne Muscular Dystrophy (DMD), will provide Prosensa with up to €5 million by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. The closing of €4.5 million of the notes is contingent upon specified milestones in the advancement of drisapersen and the Company's other exon skipping candidates in Prosensa's DMD portfolio.
Galapagos NV announced the achievement of a second partial milestone, thereby completing the nomination of a new pre-clinical candidate in the osteoarthritis alliance with Servier. On March 7, Galapagos announced the receipt of €2M as the first partial milestone. Today's payment remains undisclosed and contributes to Group revenues in the first half of 2014.
The FP7 Health project ENTENTE and EuropaBio event will gather 28 European early stage innovative companies active in the health sector and seeking investment opportunities and international exposure. The selected companies will have the opportunity to pitch their innovation, developments and needs to an international jury of about 40 business angels, venture capitalists, corporate investors and other industry experts. The deadline for applications is 29 August.
For his research on poisonous snakes Dr. Freek Vonk, researcher at Naturalis Biodiversity Center, received a VENI grant of a quarter million from the Dutch Organization for Scientific Research (NWO). Freek Vonk will use this amount to clarify the genomes of two species of poisonous snake species.
> Read more Dutch
MorphoSys and Galapagos advance Joint antibody program in Inflammatory diseases into preclinical developmentPublished : Wednesday, July 23, 2014
MorphoSys AG and Galapagos NV announced that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys' next-generation antibody library Ylanthia and will now be jointly developed in inflammatory diseases.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe